Synapse - David Hyman

Results (354)

Genome-driven paradigm for the development of selective fibroblast growth factor receptor inhibitors

Journal Article

Schram, A. M.; Voss, M. H.; Hyman, D. M.
Journal of Clinical Oncology (2017)

A phase 2 study of alisertib (MLN8237) in recurrent or persistent uterine leiomyosarcoma: An NRG Oncology/Gynecologic Oncology Group study 0231D

Journal Article

Hyman, D. M.; Sill, M. W.; Lankes, H. A.; Piekarz, R.; Shahin, M. S.; Ridgway, M. R.; Backes, F.; Tenney, M. E.; Mathews, C. A.; Hoffman, J. S.; more...
Gynecologic Oncology (2017)

Fulltext@MSK | Save

Molecular and clinical characterization of gliosarcomas

Meeting Abstract

Wu, S.; Brennan, C.; Zahir, A.; Berger, M.; Solit, D.; Hyman, D.; Huse, J.; Rosenblum, M.; Omuro, A.
Neurology (2016)

Fulltext@MSK | Save

Prevalence of clonal hematopoiesis in patients with advanced cancer

Meeting Abstract

Zehir, A.; Coombs, C. C.; Devlin, S.; Kishtagari, A.; Hyman, D. M.; Solit, D. B.; Robson, M. E.; Baselga, J.; Arcila, M. E.; Tallman, M. S.; more...
Journal of Clinical Oncology (2016)

Fulltext@MSK | Save

Serial next generation sequencing (NGS) of cell free DNA (cfDNA) and clonal evolution of AKT1 E17K mutant tumors: Analyses from patients (pts) enrolled on a phase I basket study of an AKT inhibitor (AZD5363)

Meeting Abstract

Smyth, L. M.; Reichel, J. B.; Tang, J.; Patel, J. A. A.; Meng, F.; Selcuklu, S. D.; You, D.; Samoila, A.; Schiavon, G.; Li, B. T.; more...
Journal of Clinical Oncology (2016)

Fulltext@MSK | Save

Comprehensive molecular profiling and analysis of mutual exclusivity of genetic aberrations (MEGA) of intra- and extrahepatic cholangiocarcinomas (IHC and EHC) evaluation of prognostic features and potential targets for intervention

Meeting Abstract

Lowery, M. A.; Ptashkin, R.; Jordan, E.; Berger, M. F.; Zehir, A.; Kemeny, N. E.; O'Reilly, E. M.; Jarnagin, W. R.; Harding, J. J.; DeMatteo, R. P.; more...
Journal of Clinical Oncology (2016)

Fulltext@MSK | Save

Genomic profiling of pancreas ductal adenocarcinoma (PDA), actionability, and correlation with clinical phenotype

Meeting Abstract

Jordan, E.; Lowery, M. A.; Ptashkin, R.; Zehir, A.; Berger, M. F.; Maynard, H.; Glassman, D. C.; Covington, C. M.; Schultz, N.; Abou-Alfa, G. K.; more...
Journal of Clinical Oncology (2016)

Fulltext@MSK | Save

Next generation sequencing (NGS) in lung adenocarcinoma (LA) as a guide to treatment selection

Meeting Abstract

Jordan, E.; Barron, D.; Schultz, N.; Chakravarty, D.; Kris, M. G.; Rudin, C. M.; Li, B. T.; Yu, H. A.; Drilon, A. E.; Rusch, V. W.; more...
Journal of Clinical Oncology (2016)

Fulltext@MSK | Save

Phase Ib study of BGJ398 in combination with BYL719 in patients (pts) with select advanced solid tumors

Meeting Abstract

Hyman, D. M.; Tran, B.; Jaime, J. C.; Garralda, E.; Machiels, J. P. H.; Schellens, J. H. M.; Bedard, P.; Campone, M.; Cassier, P.; Sarantopoulos, J.; more...
Journal of Clinical Oncology (2016)

Fulltext@MSK | Save

Preliminary results from the first in human study of activin-A inhibitor, STM434, in patients with granulosa cell ovarian cancer and other advanced solid tumors

Meeting Abstract

Hyman, D. M.; Rasco, D. W.; Infante, J. R.; Liu, J. F.; Welkowsky, E.; Thai, D. L.; Haqq, C. M.
Journal of Clinical Oncology (2016)

Fulltext@MSK | Save